ArticleEcancermedicalscience2026
Integrative systematic review and transcriptomic -machine learning analysis of molecular signatures in metaplastic breast cancer.
Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metaplastic breast cancer (MpBC) is a rare and aggressive breast cancer subtype characterised by marked histological heterogeneity, therapeutic resistance and poor clinical outcomes. Despite increasing molecular research, existing evidence remains fragmented, heterogeneous and poorly integrated, limiting clinical translation and biomarker validation. Methods: We developed an integrative analytical framework combining systematic review, quantitative meta-analysis, transcriptomic profiling and interpretable machine learning to identify and prioritise molecular markers in MpBC. A Preferred Reporting Items for Systematic Reviews and Meta Analyses-guided systematic review was conducted across PubMed, arXiv and Semantic Scholar. Effect sizes were standardised to Cohen's d and synthesised using a random-effects model. Transcriptomic analysis was performed on the GSE165407 dataset using DESeq2 in R (RStudio version 1.1.463), with differentially expressed genes cross-referenced against literature-derived biomarkers. Supervised models including a multi-layer perceptron and boosted random forest were applied, with performance evaluated using receiver operating characteristic analysis. Model interpretability was assessed using SHapley Additive exPlanations. Results: Eleven studies met inclusion criteria. Meta-analysis demonstrated low heterogeneity and a pooled effect size of d = 0.74 (95% CI 0.59-0.88), indicating a consistent moderate-to-large biomarker signal across studies. Pathway enrichment revealed convergence on PI3K/AKT/mTOR signalling, immune modulation and epithelial -mesenchymal transition. Transcriptomic profiling demonstrated concordance with literature-derived markers. The random forest model achieved strong classification performance (AUC = 0.91), with high specificity and minimal misclassification. SHapley Additive exPlanations analysis identified both canonical (PI3KCA, RPL39, EXO1) and non-canonical (CD55, LARGE2) contributors to model prediction. Conclusion: This study provides an integrated synthesis linking systematic evidence, transcriptomic validation and interpretable machine learning in MpBC. By reconciling fragmented literature with data-driven modelling, we identify a biologically coherent and clinically tractable molecular signature, offering a foundation for biomarker-driven stratification and translational validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.